查詢結果分析
相關文獻
- 新一代口服抗凝血劑在老年人之使用原則
- 新型口服抗凝血劑在亞洲缺血性腦中風病患之運用
- 心房顫動患者使用NOACs之臨床考量
- Sudden Cardiac Death Following Verapamil in a Patient with Wolff-Parkinson-White Syndrome and Dilated Cardiomyopathy--A Case Report and Literature Review Based on Emergency Viewpoints
- 心房顫動的最新治療
- Late Development of Persistent Atrial Fibrillation with Loss of AAI Mode Pacemaker Function and Superior Vena Cava Syndrome--Report of a Case of Sick Sinus Syndrome with Such Complications and Review of Literature
- Electrical Remodeling in Atrial Fibrillation
- 非瓣膜性心房顫動的腦中風預防
- 心房顫動病例及用藥討論
- 手術期間的心房顫動
頁籤選單縮合
題名 | 心房顫動患者使用NOACs之臨床考量=Clinical Considerations of NOACs in Patients with Atrial Fibrillation |
---|---|
作 者 | 鄭吉元; 雷青熒; 蔡慈貞; | 書刊名 | 藥學雜誌 |
卷期 | 34:1=134 2018.03[民107.03] |
頁次 | 頁13-19 |
分類號 | 418.2321 |
關鍵詞 | 心房顫動; 新型口服抗凝血劑; Atrial fibrillation; NOACs; |
語文 | 中文(Chinese) |
中文摘要 | 心房顫動 (atrial fibrillation,AF) 病人要小心發生中風,傳統上是使用 warfarin 來 預防。近來,新型口服抗凝血劑 (NOACs) 的成效及安全性皆優於 warfarin,於臨床被 廣泛使用。本文概述4個 NOACs,包括 dabigatran、rivaroxaban、apixaban、edoxaban 的藥物動力學、藥物交互作用,以及如何在常見的臨床情境下適當使用 NOACs,冀 望能對醫療人員有所助益。 |
英文摘要 | Atrial fibrillation (AF) patients had risk of stroke, warfarin was the treatment of choice for the stroke prevention in AF patients. However, the availability of novel oral anticoagulants (NOACs) had changed the landscape because these drugs offered better efficacy and safety compared to warfarin. This article summarized the pharmacokinetics, drug interaction, and clinical practice of the four NOACs including dabigatran, rivaroxaban, apixaban, edoxaban. We hope this paper will be helpful for the medical staff. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。